Sanofi-Aventis Sees India's Shantha As Global Hub For Its Biotech Plans
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - French drug maker Sanofi-Aventis sees Shantha Biotech - its latest Indian acquisition - as a hub to further its global biotech ambitions but may not rush to buy more companies in India